Industries > Pharma > Rare Diseases Market Report 2021-2031

Rare Diseases Market Report 2021-2031

Forecasts by Drugs (Revlimid, MabThera/Rituxan, Opdivo, Imbruvica, Sprycel, Tasigna, Copaxone, Rebif), by Disease (Rare Oncology Diseases, Rare Metabolic Diseases, Rare Neurologic Diseases, Rare Haematology Diseases, Rare Infectious Diseases, Other Rare Diseases), by Type (Non Biologics, Biologics), by Age (Adult, Pediatric), by End-use (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 01 March 2021
PAGES: 333
PRODUCT CODE: PHA1076
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA1076 Categories: , Tags: ,

Rare Diseases Market– Our New Study Reveals Trends, R&D Progress, and Predicted Revenues over the Next Decade
The global rare diseases market was valued at US$xx billion in 2021 and is likely to reach US$xx billion by 2026 growing at a CAGR of xx% from 2021-2026. Furthermore, the market is predicted to generate revenue of US$xx billion by 2031. Increasing cases of rare genetic diseases coupled with rising number of US FDA approvals for treatment of rare diseases is likely to promote the market growth. The growing emphasis on scientific activities and the development of new medicinal medicines has expanded the market importance of treating rare diseases.

What Are The Market Driving Factors?
• Increasing number of approvals for rare diseases
• Robust pipeline by major players
• Increasing health awareness

What Are The Market Opportunities?
• Increasing demand from emerging economies
• Increasing government support

Some of the novel drugs approved in 2020 for rare diseases
• Evrysdi
• Lampit
• Orladeyo
• Artesunate

In addition, increasing product advances are contributing to the launch of ground-breaking technical instruments for the detection of unusual genetic disorders. In addition, supportive government initiatives aimed at increasing recognition of the treatment of rare diseases are contributing to expanded implementation of successful rare disease therapies. In terms of drugs, others segment dominated the global market by generating revenue of US$xx billion in 2021 and is likely to grow at a CAGR of xx% over the forecast period.

Key highlights about rare diseases market:
• Majority of rare diseases effect new born and are diagnosed before the age of 5 years
• Genetic testing finds major application in diagnosing variety of rare diseases
• Rising number of new born screenings is expected to increase the diagnosis rate of rare diseases
• Prenatal screening finds its application in diagnosing Trisomy 13, Trisomy 18 and Edward’s disease

Discover how to stay ahead
Our 330+ pages report provides 400+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Rare Diseases Market. See how to exploit the opportunities.

CTA

Rare Diseases Market Segmentation

Drugs
• Revlimid
• MabThera/Rituxan
• Opdivo
• Imbruvica
• Sprycel
• Tasigna
• Copaxone
• Rebif

Disease
• Rare Oncology Diseases
• Rare Metabolic Diseases
• Rare Neurologic Diseases
• Rare Hematology Diseases
• Rare Infectious Diseases
• Other Rare Diseases

Type
• Non Biologics
• Biologics

Age
• Adult
• Pediatric

End use
• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Rare Diseases Market Report 2021-2031
Need industry data? Please contact us today.

COVID-19 Impact Recovery Scenarios
This report includes Baseline Forecasts along with Different Rebound Scenarios to help analyze the global rare disease market-no matter how COVID-19 affects the economy.

To access the data contained in this document please email contactus@visiongain.com

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.

Leading countries and the potential for market growth
Overall world revenue for rare disease Market will surpass $xx billion in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Rare Disease Market report helps you
In summary, our 330+ page report provides you with the following knowledge:

• Revenue forecasts to 2031 for rare disease Market, with forecasts for disease and end use, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2031 for 5 regional and 17 key national markets– See forecasts for the rare disease market in North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Also forecasted is the market in the U.S., Canada, UK, France, Germany, Italy, Spain, Russia, Denmark, Netherland, Japan, India, China, Brazil, Mexico, South Africa, and UAE among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the rare disease Market. Some of the companies profiled in this report are Pfizer Inc., Novartis AG, Merck KGaA, F. Hoffmann-La Roche Ltd, Amgen Inc., Biogen Inc., Teva Pharmaceuticals, Alexion Pharmaceuticals, Inc., Sanofi S.A., AbbVie, Bristol Myers Squibb, Takeda Pharmaceuticals, Roche, Johnson & Johnson Services, Inc.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the rare disease market and leading companies. You will find data, trends, and predictions.

Who should read this report?
• Senior Executives
• Business Development Managers
• Marketing Directors
• Consultants
• Chief Executive Officers
• Governments, agencies & organizations actively working or interested in the rare disease industry will also find significant value in our research.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Rare Diseases Market Report 2021-2031: Forecasts by Drugs (Revlimid, MabThera/Rituxan, Opdivo, Imbruvica, Sprycel, Tasigna, Copaxone, Rebif), by Disease (Rare Oncology Diseases, Rare Metabolic Diseases, Rare Neurologic Diseases, Rare Haematology Diseases, Rare Infectious Diseases, Other Rare Diseases), by Type (Non Biologics, Biologics), by Age (Adult, Pediatric), by End-use (Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Rare Diseases Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Rare Diseases Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories